Leadership Overview
Alnylam Pharmaceuticals has 5 executives leading key functions including strategy, commercialization, financial operations, franchise management, and legal compliance.
Driven by a commitment to RNA interference technology, Alnylam Pharmaceuticals advances novel therapeutics to address genetic diseases and improve patient outcomes through scientific innovation.
Driven by a commitment to RNA interference technology, Alnylam Pharmaceuticals advances novel therapeutics to address genetic diseases and improve patient outcomes through scientific innovation.
Leadership Roles at Alnylam Pharmaceuticals
Yvonne Greenstreet - Chief Executive Officer
Yvonne Greenstreet, the Chief Executive Officer at Alnylam Pharmaceuticals, directs the overarching corporate strategy and long-term vision for RNAi therapeutic development. Greenstreet oversees the integration of research, clinical development, and commercial operations to ensure the delivery of life-changing medicines for patients with rare genetic conditions. By fostering strategic collaborations with global partners, the Chief Executive Officer expands the reach of the company's pipeline into new therapeutic areas like hypertension and Alzheimer's disease. This leadership role involves constant engagement with the Board to align operational milestones with shareholder value. Through rigorous oversight of the drug development lifecycle, Yvonne Greenstreet maintains the company's position as a leader in the biopharmaceutical sector. Ultimately, Greenstreet drives the organizational culture toward scientific excellence and sustainable growth across international markets.
Jeff Poulton - Chief Financial Officer
Jeff Poulton, the Chief Financial Officer at Alnylam Pharmaceuticals, manages the financial health and capital allocation strategies necessary to support intensive research and development programs. Poulton oversees the budgeting, financial reporting, and investor relations functions, ensuring transparency and fiscal discipline across all departments. By evaluating the economic viability of clinical trials and potential licensing agreements, the Chief Financial Officer provides the analytical foundation for the company's expansion into new disease areas like NASH and chronic HBV infection. This leadership role involves managing the balance sheet to sustain long-term investment in RNAi technology while navigating complex global regulatory environments. Jeff Poulton directs the financial planning processes that enable the company to scale operations effectively. Ultimately, Poulton ensures the financial stability required to advance the company's mission of delivering transformative medicines to patients worldwide.
Shweta Randeria - Chief Marketing Officer
Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, architects the global commercialization strategies for the company's portfolio of RNAi therapeutics. Randeria manages the market positioning and patient access initiatives for products such as ONPATTRO and AMVUTTRA, ensuring these treatments reach the populations requiring intervention for hATTR amyloidosis. Overseeing the development of brand narratives, the Chief Marketing Officer aligns marketing efforts with clinical data to demonstrate therapeutic value to healthcare providers and payers. This role requires close coordination with regional sales teams to optimize product launches across diverse healthcare systems. By analyzing market trends and patient needs, Shweta Randeria identifies opportunities for expanding the footprint of existing therapies. Ultimately, Randeria secures the commercial success of the company's innovative medicine suite through data-driven engagement and strategic market penetration.
Carlo Cristobal - Head To of & Ttr Franchise Chief of Staff (US)
Carlo Cristobal, the Head To of & Ttr Franchise Chief of Staff (US) at Alnylam Pharmaceuticals, coordinates the operational execution of the TTR franchise within the North American market. Cristobal manages the cross-functional alignment between clinical, medical affairs, and commercial teams to ensure the seamless delivery of treatments for ATTR amyloidosis. Overseeing the day-to-day operations of the franchise, the Head To of & Ttr Franchise Chief of Staff (US) streamlines internal processes to accelerate decision-making and improve patient support services. This role involves translating high-level corporate objectives into actionable regional plans that drive product adoption and clinical integration. By monitoring performance metrics and operational bottlenecks, Carlo Cristobal optimizes the efficiency of the franchise. Ultimately, Cristobal supports the company's goal of establishing a dominant presence in the treatment of transthyretin-mediated diseases through focused operational leadership.
Bryan Supran - Chief Legal Officer
Bryan Supran, the Chief Legal Officer at Alnylam Pharmaceuticals, directs the legal, compliance, and intellectual property strategies that protect the company's proprietary RNAi technology. Supran oversees the negotiation of complex collaboration and licensing agreements with global partners such as Roche and Novartis, ensuring that all partnerships align with the company's strategic interests. By managing the legal framework for clinical trials and regulatory filings, the Chief Legal Officer mitigates risk while facilitating the rapid advancement of the drug pipeline. This role involves providing counsel on corporate governance and ensuring adherence to international healthcare regulations. Bryan Supran leads the legal team in defending the company's patent portfolio against potential infringements. Ultimately, Supran provides the essential legal infrastructure that allows the company to innovate and commercialize novel therapeutics with confidence and integrity.
Explore Leadership Teams in Manufacturing
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes and enhance quality of life. Guided by a long-standing commitment to scientific research and medical advancement, the company focuses on addressing some of the world’s most significant health challenges through breakthrough therapies and healthcare solutions.
Company Leadership TW
JS
TD
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes medicines for serious diseases with significant unmet medical needs. Its portfolio includes therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also advances research programs in kidney disease, type 1 diabetes, myotonic dystrophy, and other genetic disorders, serving patients through healthcare providers, specialty pharmacies, hospitals, and distributors worldwide.
Company Leadership GL
AL
OG
PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.
Company Leadership BP
HL
BK
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
NB
Frequently Asked Questions Regarding Alnylam Pharmaceuticals Top Executives and Leadership Team
